Randomized trial: nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma
6 Apr, 2018 | 01:34h | UTCNivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma – NEJM (link to abstract – $ for full-text)
Quick Take Video Summary: Sunitinib or Nivolumab plus Ipilimumab for Renal-Cell Carcinoma (free)
“Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab”.